X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference
Globe Newswire (Wed, 9-Sep 7:00 AM ET)
X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting
Globe Newswire (Tue, 8-Sep 7:00 AM ET)
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Tue, 1-Sep 4:30 PM ET)
X4 Pharmaceuticals Secures EU Milestone and Maintains Strong Cash Position Into 2029
Market Chameleon (Fri, 7-Aug 7:31 AM ET)
X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Thu, 6-Aug 4:15 PM ET)
Globe Newswire (Wed, 1-Jul 7:00 AM ET)
Market Chameleon (Fri, 24-Oct 6:30 AM ET)
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
X4 Pharmaceuticals trades on the NASDAQ stock market under the symbol XFOR.
As of September 18, 2026, XFOR stock price climbed to $3.58 with 956,855 million shares trading.
XFOR has a beta of 1.75, meaning it tends to be more sensitive to market movements. XFOR has a correlation of 0.12 to the broad based SPY ETF.
XFOR has a market cap of $354.95 million. This is considered a Small Cap stock.
Last quarter X4 Pharmaceuticals reported $9 million in Revenue and -$.13 earnings per share. This beat revenue expectation by $7 million and exceeded earnings estimates by $.06.
In the last 3 years, XFOR traded as high as $48.00 and as low as $1.35.
The top ETF exchange traded funds that XFOR belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
XFOR has outperformed the market in the last year with a return of +17.8%, while the SPY ETF gained +16.7%. However, in the most recent history, XFOR shares have underperformed the stock market with its stock returning -11.6% in the last 3 month period and -11.4% for the last 2 week period, while SPY has returned +3.3% and -1.5%, respectively.
XFOR support price is $3.35 and resistance is $3.65 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XFOR shares will trade within this expected range on the day.
